Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (294)	2/12/1999 10:17:00 AM
From: Guy	Read Replies (2) \| Respond to of 5582

reThis is another way that GelTech could position Zicam in the market. It could be positioned as a product that significantly reduces the duration of the common cold and can be used with other medications like aspirin for aches and fever or Sudafed for sinus pressure. One benefit to this is that Zicam would not be competing with other cold remedies. I believe that Zicam has the potential to create an entirely new segment of the market for cold remedies. It really depends on how GelTech decides to market and position the product. Dan, very interesting information. However, I wonder if GelTech could make such claims (even if valid) without clinical trials. I must say, that so far, it seems that Ziacam has been working well for all who have tried it. Like others, I wish I would get a cold myself, just so I could try the stuff out myself. Good Investing, Greg